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Ethnopharmacological  relevance:  The  increasing  use  of  traditional  herbal  medicines  around  the  world
requires  more  scientiﬁc  evidence  for their  putative  harmlessness.  To  this  end,  a  plethora  of  methods  exist,
more or  less  satisfying.  In  this  post-genome  era,  recent  reviews  are  however  scarce,  not  only  on  the  use
of  new  “omics”  methods  (transcriptomics,  proteomics,  metabonomics)  for  genotoxicity,  teratogenicity,
and  nephrotoxicity  assessment,  but  also on  conventional  ones.
Methods:  The  present  work  aims  (i)  to  review  conventional  methods  used  to assess  genotoxicity,  terato-
genicity  and nephrotoxicity  of  medicinal  plants  and  mushrooms;  (ii)  to report  recent  progress  in the  use
of “omics”  technologies  in  this  ﬁeld;  (iii)  to  underline  advantages  and  limitations  of  promising  methods;
and  lastly  (iv)  to  suggest  ways  whereby  the  genotoxicity,  teratogenicity,  and  nephrotoxicity  assessment
of  traditional  herbal  medicines  could  be more  predictive.
Results:  Literature  and  safety  reports  show  that  structural  alerts,  in  silico  and  classical  in  vitro  and  in vivo
predictive  methods  are  often  used.  The  current  trend  to  develop  “omics”  technologies  to assess  genotox-
icity,  teratogenicity  and  nephrotoxicity  is  promising  but  most  often  relies  on  methods  that  are still not
standardized  and  validated.
Conclusion:  Hence,  it is critical  that  toxicologists  in  industry,  regulatory  agencies  and  academic  institutions
develop  a  consensus,  based  on  rigorous  methods,  about  the  reliability  and  interpretation  of endpoints.  It
regul
s.will also  be important  to 
new “omics”  technologie
. IntroductionHerbal medicines have a long history of use for the preven-
ion and treatment of diseases; their use can be traced back to
he ﬁrst written testimonies of humanity, through antiquity and
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Open access under CC BY-NC-ND license.ate  the  integration  of  conventional  methods  for  toxicity  assessments  with
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middle ages till modern time (Williamson, 2003). They have always
been part of human culture. According to the World Health Orga-
nization (WHO), nearly 80% of the world populations still rely on
medicinal herbs for their primary health care. Herbal medicines
are then widely used around the world, and increasingly so in
Western nations (Winslow and Kroll, 1998; Jordan et al., 2010). For
instance, 71% of the population in Canada (IPSOS-Reid, 2005) and
80% in Germany (Thomas et al., 2001) used, in their lifetime, tradi-
tional medicines under the wording “complementary and alternative
medicine”. In the United States, about 19% of the adult populations
Open access under CC BY-NC-ND license.are using herbal medicinal products (Kennedy, 2005; Patwardhan
et al., 2005); the herb supplement sales have increased in USA by
23% from 2000 to 2010, reaching a market of more than 5 billion
dollars (NBJ, 2011). Europe was  estimated to import in 2004 about
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00,000 tons of medicinal plants per annum, with an average mar-
et value of US$ 1 billion from Africa and Asia (Wakdikar, 2004).
esides, in developing countries, WHO  strongly encourages the
se of traditional herbal medicines in primary health care delivery
ystem (Atsamo et al., 2011).
Even for efﬁcient and documented herbal medicinal products,
he toxicity can be relatively unexplored; indeed, in contrast with
onventional drugs research and development, the toxicity of tra-
itional herbal medicines is not often evaluated (Hartmann et al.,
004; Suter, 2006; Smart et al., 2011). Most of the population how-
ver does not pay attention, believing that, if these products have
een used so far, they should be devoid of toxicity (Cosyns et al.,
994; Tanaka et al., 1997a,b; Stengel and Jones, 1998; Lord et al.,
999; Luyckx and Naicker, 2008). In the era of post-genome and
ioinformatics, innovations in genomics, proteomics and metabo-
omics (Cho, 2007; Li, 2007; Kang, 2008; Lao et al., 2009) can play
n important role in assessment of the genotoxicity, teratogenicity
nd nephrotoxicity of plant-based medicinal products. However,
ecent reviews are scarce, not only for post-genomic era but also
or conventional methods.
The present work aims to (i) review conventional methods used
o assess genotoxicity, teratogenicity and nephrotoxicity and their
pplication to herbal medicinal products; (ii) report recent progress
n the use of “omics” technologies to detect these toxicities, with
mphasis on the application to herbal products and mushrooms;
iii) analyze the advantages and limitations of each approach; and
astly (iv) suggest ways whereby the genotoxicity, teratogenicity,
nd nephrotoxicity assessment of plants-based medicinal products
ould be more predictive. The different methods discussed are pre-
ented in Fig. 1.
. Part A: methods for genotoxicity assessment
Genotoxicity can be due to many physico-chemical agents that
esult in a wide variety of possible damages to the genetic mate-
ial, ranging from various DNA adducts to single- and double-strand
reakages, DNA–DNA and DNA–protein cross-links or even chro-
osomal breakage (Ogura et al., 2008; Cavalcanti et al., 2010;
ang et al., 2012). The major challenge in genotoxicity test-
ng resides in developing methods that can reliably and sensibly
etect either such a vast array of damages or a general cellular
esponse to genotoxic insult. It is recognized that no single test can
etect every genotoxin, therefore the concept of tests battery has
een implemented in many regulatory guidelines (Billinton et al.,
008).
In the last decades, numerous damage signalization and repair
echanisms, complex and extremely efﬁcient, have been unrav-
lled, both in prokaryote, eukaryote and mammalian systems
Moller and Wallin, 1998; Bootsma et al., 2001). Although DNA
lterations, both in the sequence of nucleotides and in the arrange-
ent of DNA strands, can also arise from mistakes in the repair
rocess, agents interfering with damage signalization and repair
echanism are generally not considered in safety testing. They
hould however be detected as they could impair indirect geno-
oxicity by facilitating the activity of genotoxic agents such as
irect genotoxins, reactive oxygen species, and radiations (UV,
) (Johnson and Loo, 2000; Kelly et al., 2001; Azqueta et al.,
009).
.1. Conventional methods
The Organization for Economic Co-operation and Develop-
ent (OECD, 2012) and the European Centre for the Validation of
lternative Methods (ECVAM, 2012) have largely investigated the
alidation of mutagenicity tests and should be refered to for more
etails.armacology 140 (2012) 492– 512 493
2.1.1. Detection of phytochemical compounds bearing structural
alerts for genotoxicity activity
Structural alerts or “toxicophores” are deﬁned as molecules or
molecular functionalities that are associated with toxicity. Their
presence in compounds or a molecular structure alerts the inves-
tigator to their potential toxicity (Jacobson-Kram and Contrera,
2007). A few well-characterized compounds include (i) 1–2 unsat-
urated pyrrolizidine alkaloids esters from many Boraginaceae,
Asteraceae and Fabaceae (Prakash et al., 1999b; Fang et al., 2011)
that exhibit a large variety of genotoxicities, including DNA binding,
DNA cross-linking, DNA–protein cross-linking, sister chromatid
exchange, and chromosomal aberrations (Roeder, 2000; Fu et al.,
2001, 2002a, 2004); (ii) aristolochic acids (AA), nitro-polyaromatic
compounds responsible for terminal nephropathies observed after
intoxication by many Aristolochia species (Fang et al., 2011); a series
of studies conﬁrmed that they are genotoxic in both bacterial and
mammalian cells, yielding highly persistent and non-repaired DNA
adducts; (iii) allylalkoxybenzenes (e.g. eugenol, methyleugenol,
estragole), safrole (4-allyl-1,2-methylenedioxybenzene) and -
asarone, potentially genotoxic components from some essential
oils (Liu et al., 2004; Munerato et al., 2005; Zhang et al., 2005;
Smith et al., 2010). The notion of threshold for genotoxic insult
is still a matter of heavy debates; consequently such compounds
should be proscribed from herbal medicines or at least severely
limited.
2.1.1.1. Analytical methods. Analytical methods with suitable
detection limits have been developed for the characterization and
quantiﬁcation of many known molecules or molecular functionali-
ties associated with genotoxicity; they are now being implemented
in ofﬁcial pharmacopeias. Such methods are based on spectropho-
tometry (the Ehrlich reagent for pyrrolizidine alkaloids), thin layer
chromatography (TLC), gas chromatography/mass spectroscopy
(GC/MS) and liquid chromatography/mass spectroscopy (LC/MS
and LC/MS/MS) (Fu et al., 2002b, 2007; Zenga et al., 2007; Napoli
et al., 2010).
2.1.1.2. In silico methods. These predictive methods generally refer
to a computational experiment, mathematical calculation, or sci-
entiﬁc analysis of substances data through a computer-based
analysis (Valerio-Jr, 2009). Computer models used for genotoxi-
city prediction fall into three principal categories (Votano et al.,
2004): (i) rule-based expert systems such as DEREK that esti-
mates the presence of a DNA-reactive moiety in a given molecule
(Greene, 2002); (ii) quantitative structure–activity relationship
models (QSAR) such as TOPKAT that uses “electro-topological”
descriptors (atom-type, bond-type and group-type E-state) rather
than chemical structure to predict mutagenic reactivity with DNA
(Wolfgang, 2000; Mattioni et al., 2003; Serra et al., 2003; Votano
et al., 2004; Snyder and Smith, 2005); and (iii) three-dimensional
computational DNA-docking model to identify molecules capable
of non-covalent DNA interaction (Snyder et al., 2004; Snyder and
Smith, 2005).
In silico prediction systems are cheaper, rapid, have higher
reproducibility, have low compound synthesis requirements, can
undergo constant optimization, and have potential to reduce or
replace the use of animals (Hofer et al., 2004; Valerio-Jr, 2009).
Their limitations are the lack of available toxicity data, inappro-
priate (simplistic) modeling of some endpoints, and poor domain
applicability of models (Cronin, 2002). The application of in silico
methods to complex mixtures such as herbal extracts is by evidence
limited to the detection of known phytochemical compounds bear-
ing known or new structural alerts for genotoxicity activity; they
could however help to elucidate which compounds are responsible
for a proven effect.
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.1.2. In vitro methods for genotoxicity assessment
By evidence, the absence of known phytochemical compounds
earing structural alerts for genotoxic activity in an herbal medicine
oes not mean the absence of potential genotoxicity. It is highly
ossible that many genotoxic natural molecules have not been
dentiﬁed yet and, therefore, complementary testing methods have
een developed.
.1.2.1. Investigations on non-mammalian cells. All these tests can
e performed both in the absence and in the presence of an
xogenous metabolizing system, often a rat liver S9 (microsomal)
uspension.
2.1.2.1.1. Prokaryotic organisms: the Ames test. The Ames test,
 bacterial reverse mutation assay, is performed with histidine-
ependent auxotrophic mutants of Salmonella typhimurium (strains
A97, TA98, TA100, TA102, TA1535, TA1537, etc.) or tryptophan
ependent auxotrophic mutants of Escherichia coli (WP2 isogenic
trains uvr) (Maron and Ames, 1983). In the presence of a muta-
enic agent, a selective pressure, from a medium depleted in the
ssential amino acid, results in reverse mutations and the growth
f colonies that are simply counted. Several different strains of
almonella must be used, because each strain individually assays
or a particular type of mutagen (i.e., one strain for base pair sub-
titutions and a separate strain for frameshift mutations) (Ramos
t al., 2002; Zhang et al., 2004; Marshall, 2007; Ogura et al.,
008).
2.1.2.1.2. Prokaryotic organisms: tests based on the SOS response.
he response of Escherichia coli and Salmonella typhimurium to
enotoxic agents involves the triggering of a complex system of
enes known as the “SOS response”. The SOS-chromotest proce-
ure is based on the Escherichia coli PQ37 strain in which the
-galactosidase (-Gal) gene, lacZ, is placed under the control of
ﬁA, one of the SOS genes, through an operon fusion (Quillardet and
ofnung, 1985; Emig et al., 1996; Nair et al., 2000; Nieminen et al.,
002). The Vitotox assay involves genetically modiﬁed Salmonella
yphimurium that harbor a luciferase gene under control of the recNicity, teratogenicity and nephrotoxicity assessment methods.
or pr1 promoter. In the presence of a DNA damaging compound, the
SOS response leads to -Gal or luciferase expression, respectively,
which is then an indirect measure of the genotoxic activity of a
test compound. The bacterial toxicity needs to be assessed, e.g. by
measurement of alkaline phosphatase (Nieminen et al., 2002). The
Vitotox test has a high predictivity for bacterial mutagenicity and
the number of false-positive scores due to cytotoxicity is relatively
low (Westerink et al., 2009, 2010).
2.1.2.1.3. Eukaryotic organisms: Saccharomyces cerevisiae. The
most widely used Saccharomyces cerevisiae assay, proposed by Zim-
mermann et al. in 1975 (Sanchez-Lamar et al., 2002; Nohynek
et al., 2004), relies on the diploid D7 strain. When com-
pounds mutate the DNA of this yeast strain, easily scorable
phenotypes (color of colonies, growth on particular media)
are produced at three separate genomic sites. Additionally,
each one of these phenotypic changes speciﬁes a separate
type of mutation and repair mechanism (Marshall, 2007). The
RadarScreen assay is based on a RAD54 promoter-linked -Gal
reporter assay in yeast; RAD54 is involved in DNA recombina-
tion events and repair mechanisms, especially those involving
double-stranded DNA breaks during both mitosis and meiosis.
Upon DNA damage and -Gal expression, the substrate d-luciferin-
o--galactopyranoside liberates luciferin that is luminometrically
measured (Westerink et al., 2009). The RadarScreen assay has a
high predictivity for clastogenicity; the number of false-positive
scores due to cytotoxicity is relatively low (Westerink et al., 2009,
2010).
2.1.2.1.4. Eukaryotic organisms: Aspergillus nidulans. Because
of its parasexual cycle, the ﬁlamentous fungus Aspergillus nidulans
constitutes an excellent system for studying mitotic crossing-
over, since its cells spend a substantial part of their cell cycle
in the G2 phase during the germination period; two  copies of
each chromosome during that period of the cell cycle signiﬁ-
cantly favors a mitotic recombination event, visually detected
by simple plating tests (Osman et al., 1993; Souza-Júnior et al.,
2004).
hnoph
s
a
t
e
c
i
s
m
c
m
m
m
m
a
m
e
w
a
n
c
(
K
t
p
f
L
r
2
a
m
o
u
i
(
i
D
e
t
i
i
r
m
e
2
o
t
e
m
2
t
m
t
t
i
2
i
o
m
1
g
2M.  Ouedraogo et al. / Journal of Et
2.1.2.1.5. Investigations on mammalian cells. There are circum-
tances where the performance of the above tests does not provide
ppropriate or sufﬁcient information for the assessment of geno-
oxicity. The ﬁrst circumstance is the case of compounds that are
xcessively toxic to microorganisms (e.g. antibiotics, antifungal
ompounds). It is also the case of compounds thought or known to
nterfere with the mammalian cell replication system (e.g. topoi-
omerase inhibitors, nucleoside analogues or inhibitors of DNA
etabolism) that most likely will not be detected. Guidelines
onsequently recommend performing additional in vitro mam-
alian cell tests. Different cell lines are used, some of which are
etabolically competent to allow detection of genotoxins needing
etabolic activation. Alternatively, for non-metabolizing cell lines,
icrosomal or S9 activation as in the Ames test can be applied.
2.1.2.1.6. In vitro micronucleus assay. The in vitro micronucleus
ssay is considered as a routine screening test for the rapid assess-
ent of chromosomal aberrations (Miller et al., 1998; von der Hude
t al., 2000). Micronuclei are acentric chromosomal fragments or
hole chromosomes left behind during mitotic cellular division,
ppearing in the cytoplasm of interphase cells as small additional
uclei (Bolognesi, 2003). Micronuclei induction can result from
lastogens (agents that induce chromosomal breaks) or aneugens
agents that induce mainly chromosomal gain/loss) (Fenech, 2000;
irsch-Volders et al., 2003). Cells treated with test compound are
hen grown in the presence of cytochalasin-B to prevent the cyto-
lasmic division after nuclear division, ﬁxed, stained and scored
or binucleated and micronucleated cells (Fenech, 2000; Sanchez-
amar et al., 2002). The detection of micronuclei, manual or, as more
ecently described, automated (Diaz et al., 2007; Westerink et al.,
011), provides a readily measurable index of chromosome break-
ge and loss. Although the test is unable to provide a measure of
ore subtle changes, such as balanced translocations, such a level
f detail is in most cases unnecessary (Fenech, 1997).
2.1.2.1.7. Unscheduled DNA synthesis (UDS) assay. The
nscheduled DNA synthesis (UDS) assay measures chemical-
nduced DNA excision repair by detecting labeled thymidine
3H-TdR) incorporation. The induction of DNA repair mechanisms
s presumed to have been preceded by DNA damage, indicating the
NA damaging ability of a chemical (Lambert et al., 2005; Bakkali
t al., 2008). A core limitation of the UDS assay is its inability
o indicate if a xenobiotic is mutagenic; indeed, it provides no
nformation regarding the ﬁdelity of DNA repair and it does not
dentify DNA lesions handled by mechanisms other than excision
epair (Lambert et al., 2005).
2.1.2.1.8. Sister chromatid exchanges (SCE) assay. Various cyto-
olecular protocols have been used to perform the sister chromatid
xchanges (SCE) assay (Djelic et al., 2006; Kaya and Topaktas,
007; Bakkali et al., 2008; Hseu et al., 2008). This method relies
n the differential staining of sister chromatids during replication
o visualize reciprocal genetic exchanges between them. Such an
xchange arises when, during DNA replication, two sister chro-
atids break and rejoin with one another (Wilson and Thompson,
007); this natural mechanism is increased by exposure to geno-
oxic agents capable of inducing DNA damage (Djelic et al., 2006).
2.1.2.1.9. Mouse lymphoma assay (MLA). This assay exploits
ouse lymphoma cells (L5178Y tk+/− 3.7.2C), heterozygous at the
hymidine kinase locus (Tk1) on chromosome 11. Inactivation of
he tk+ allele (Tk1b) induces triﬂuorothymidine resistance, allow-
ng easy selection of tk−/− mutants (Clive et al., 1987; Nohynek et al.,
004; Isbrucker et al., 2006). MLA  can detect a variety of mutations,
ncluding point mutations and small mutations within Tk1, losses
f Tk1b or larger deletions including Tk1b. In contrast to the in vitro
icronucleus test, MLA  also detects translocations (Liechty et al.,
998). Most of the substances that are positive in this mammalian
ene-mutation test also induce clastogenic effects (Kirkland et al.,
011).armacology 140 (2012) 492– 512 495
2.1.2.1.10. In vitro comet assay (single-cell gel electrophore-
sis assay). In this well-established, highly sensitive, rapid, and
simple genotoxicity test, isolated cells embedded in agarose
are lysed, washed to remove membranes and proteins, brieﬂy
electrophoresed, stained and examined under epiﬂuorescence
microscopy; strand breaks, coming from either strand breakage
or excision repair, result in DNA extending towards the anode in
a structure resembling a “comet” (Singh et al., 1988; Speit et al.,
2009; Berthelot-Ricou et al., 2011). Depending on experimental
conditions, the migrating DNA (comet tail or derived parameters)
reﬂects the amount of single- or double-strand breaks, alkali-
labile sites, including incomplete excision repair sites, but also
of DNA–DNA and DNA–protein cross-links (Duez et al., 2003;
Speit et al., 2005; Speit and Henderson, 2005; Santos et al., 2009;
Verschaeve et al., 2010). A broad spectrum of DNA damage can then
be detected either by visual classiﬁcation of comet morphologies
(“visual scoring”) (Ramos et al., 2001; Cavalcanti et al., 2010) or
from morphological parameters obtained by image analysis and
integration of intensity proﬁles using in-house or commercially
available systems. There are only few limitations of the comet assay
with regard to its application and interpretation. Short-lived pri-
mary DNA lesions such as single strand breaks, which may  undergo
rapid DNA repair, could be missed when using inadequate sam-
pling times. Another limitation is that indirect mechanisms related
to cytotoxicity (e.g. DNA fragmentation in apoptosis) can lead to
positive effects (Speit et al., 2005).
2.1.2.1.11. H2AX assay. The phosphorylation of the carboxyl-
tail of a speciﬁc variant of the H2A histone protein, H2AX, at Serine
139, to become H2AX, occurs at sites ﬂanking DNA double-strand
breaks (DSBs). The measurement of H2AX by a labeled mono-
clonal antibody and microscopy (determination of foci number) or
ﬂow cytometry (Muslimovic et al., 2008; Smart et al., 2011) allows
detection of potential genotoxic activity (Watters et al., 2009; Smart
et al., 2011). The H2AX assay was  found capable of detecting DNA
damage at levels 100-fold below the detection limit of the alkaline
comet assay (Verschaeve et al., 2010).
2.1.2.2. Advantages and limitations of in vitro genotoxicity assays.
It is recognized that in vitro genotoxicity assays are extremely
useful. Their set-ups are small and use minimal amounts of test
substances, allowing low costs, high numbers of replicates, minia-
turization and automation; they have generally been validated to
detect an impressive number of genotoxic agents and mechanisms.
However, these simple cellular models are often thought to be a
too reductionist approach. The main limitations of in vitro mod-
els include the artiﬁcial and non-physiological conditions in which
the cells are maintained which do not reﬂect the body tempera-
ture, the blood electrolyte concentrations, the extracellular matrix
or the extent of cell–cell interactions within tissues. Most cell
systems represent only one cell type, often cancerous in origin,
with uncertain DNA damage signalization and repair status and
possibly further degenerated during maintenance culture. More-
over, culture media are not always homeostatic during experiments
(Hartung, 2011).
2.1.3. In vivo methods for genotoxicity assessment
In order to overcome some limitations of the in vitro investiga-
tions, in vivo methods have been also developed, not to replace
them, but to complete their information on a whole organism.
Despite the mainstream willingness to substitute animal experi-
mentation with in vitro models, animal studies remain the core
component of toxicity assessment of drugs and plant-based medic-
inal products. Number of test animals, gender, suitable controls
and dose and time parameters are important components of these
experiments and are generally speciﬁed in the relevant guide-
lines (Hartung, 2011). At various periods after the treatment, blood
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amples are collected by venipuncture (usually from the tail), the
nimals are sacriﬁced and organs (liver, kidney, femurs, tibias . . .)
re removed for the analysis.
.1.3.1. In vivo micronucleus assay. Blood sample and bone marrow
re collected by venipuncture and removed from the femur, respec-
ively; they are then smeared, stained and scored as described for
he in vitro assay. As a measure of toxicity of test compounds on
one marrow, the polychromatic erythrocytes: normochromatic
rythrocytes ratio is scored; the incidences of micronuclei are also
alculated to highlight clastogenic properties (Chen et al., 2001; da
ilva et al., 2002; Nohynek et al., 2004). The frequency of micronu-
leated reticulocytes can also be determined (Leopardi et al., 2005).
.1.3.2. In vivo unscheduled DNA synthesis (UDS) assay. The in vivo
DS is generally evaluated in the hepatocytes of treated animals
ollowing the same detection systems as its corresponding in vitro
odel.
.1.3.3. Mouse spot test. The “mouse spot test”, a rapid screening
est to detect gene mutations and recombinations in mice somatic
ells (Lambert et al., 2005), is based on the observation that geno-
oxic compounds can induce color spots on the coat of mice exposed
n utero. The color spots arise when mouse melanoblasts, heterozy-
ous for several recessive coat color mutations, lose a dominant
llele through a gene mutation, chromosomal aberration or recip-
ocal recombination, allowing the recessive gene to be expressed
Lambert et al., 2005; Wahnschaffe et al., 2005).
.1.3.4. Transgenic rodent (TGR) mutation assay. Transgenic ani-
als carry multiple copies of chromosomally integrated plasmid
nd phage shuttle vectors that harbor reporter genes to detect,
uantify and sequence mutations in vivo. The frequency of muta-
ions occurring in the animal is scored by recovering the shuttle
ector and analyzing the phenotype of the reporter gene in a bac-
erial host; molecular analysis of the gene can provide further
ig. 2. Testing strategy for “omics” methods. An in vitro or in vivo model is exposed to a
f  the model is evaluated by an “omics” method and possible/likely biomarkers of expo
ixture  or to an herbal extract, a similar pattern of response indicates probable toxicolo
umans, experimenters additionally may  have access to patients body ﬂuids (urine, blood
ut  also for patient’s monitoring.armacology 140 (2012) 492– 512
mechanistic information (Lambert et al., 2005). Some deletions and
insertion mutations may  however not be detected in phage-based
TGR. The test does not involve a large number of animals and a
major advantage is that mutations can be evaluated in any tissue;
the protocol is reproducible but requires well-trained experts, is not
yet automated and the assay cost is superior to most of the other
genotoxicity assays (Lambert et al., 2005). Some cell lines have been
derived from the in vivo TGR models and are similarly used in vitro
(Ryu et al., 1999; McDiarmid et al., 2002).
2.1.3.5. In vivo comet assay. After treatment and sacriﬁce of ani-
mals, blood lymphocytes and/or cells, dissociated from organs by
mincing a small piece into very ﬁne fragments, are treated as per
the same protocols as in vitro studies (Chiu et al., 2000; da Costa
Lopes et al., 2000; Cavalcanti et al., 2010). The in vivo comet assay
detects low levels of DNA damage, requiring small numbers of cells
per sample (Brendler-Schwaab et al., 2005).
2.1.3.6. Somatic mutation and recombination test (SMART). In view
of minimizing the number of higher organisms used in toxicologi-
cal research, a somatic mutations and recombination test (SMART)
in the wings of Drosophila melanogaster (“wing-spot test”) has been
developed. This test, based on the loss of heterozygosity for two
recessive markers (Idaomar et al., 2002; Carmona et al., 2011b),
is a tool to evaluate gene mutations, chromosome aberrations
and rearrangements related to mitotic recombination (Munerato
et al., 2005). Recently, the comet assay has been adapted to be
used in vivo in Drosophila melanogaster (Carmona et al., 2011a,b;
Sharma et al., 2011).
2.2. “Omics” technologiesThe term “omic” is derived from the Latin sufﬁx “ome” meaning
mass or many. “Omics” studies involve a high number of mea-
surements per endpoint to acquire comprehensive, integrated
understanding of biology and to simultaneously identify the
 chemically deﬁned toxic with known properties (“prototoxicant”); the response
sure are examined. When the same model is exposed to an unknown compounds
gical concern. For traditional medicinal herbs or drugs that are classically used in
) to investigate for eventual toxicity biomarkers, an important avenue for research
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Toxicometabonomics1 concern the analysis, either in organs,
blood or urine, of metabolites and metabolic pathways modiﬁca-
tions that follow a toxic insult (Ulrich-Merzenich et al., 2007b).M.  Ouedraogo et al. / Journal of Et
ifferent factors (e.g., genes, RNA, proteins and metabolites) rather
han each of those individually (Lay et al., 2006). “Toxicogenomics”
Borner et al., 2011) aim to study the interaction between the
tructure and activity of the genome and the adverse biological
ffects of exogenous agents (Bishop et al., 2001). This discipline
s based on the concept that the toxic effects of xenobiotics on
iological systems are generally reﬂected at cellular level by their
mpact on the expression of genes (transcriptomics) and proteins
proteomics) and on the production of small metabolite (metabo-
omics) (Fig. 2) (Aardema and MacGregor, 2002; Marchant, 2002;
eijne et al., 2005; Marques et al., 2011; Borner et al., 2011).
.2.1. Transcriptomics
Transcriptomics analyze the expression level of genes by
easuring the transcriptome, the genome-wide mRNA expres-
ion (Davies, 2010; Wilson et al., in press). Transcriptomics uses
igh density and/or high-throughput methods of assessing mRNA
xpression.
.2.1.1. Microarrays and qrt-PCR. Microarrays (“DNA microarrays”,
DNA arrays”, “DNA chips”, “biochips”, “gene chips”), the most
ommon approach used for gene expression proﬁling (Davies,
010), are generated by immobilizing a high number of oligonu-
leotides on an extremely small surface (up to 200,000 spots/cm2).
ased on the target sequences, signiﬁcant changes of mRNA can
e estimated for thousands of genes (Eisenbrand et al., 2002;
beremm et al., 2005; Ulrich-Merzenich et al., 2007b). Special-
zed sub-sets of gene expression changes and quantitative real-time
everse transcriptase-polymerase chain reactions (qrt-PCR)-based
pproaches that focus on speciﬁc genes have also been devel-
ped. The latter is a highly recommended conﬁrmatory tool for
uantifying gene expression with improvements in sensitivity and
peciﬁcity (Wilson et al., in press).
.2.1.2. Open systems. Other technologies such as serial analysis of
ene expression (SAGE) (Velculescu et al., 1995), massively paral-
el signature sequencing (MPSS) (Brenner et al., 2000) and total
ene expression analysis (TOGA) (Sutcliffe et al., 2000) are also
uccessfully used to detect changes in transcriptomes. In con-
rast to microarray technology (which can only measure transcript
bundances with pre-selected, known probe sequence), these
pproaches are “open systems” and thus suited for gene discov-
ry; they offer linear gene expression quantiﬁcation over a wide
ynamic range (Kussmann et al., 2006).
.2.1.3. Speciﬁc genes targeting. Published microarrays genomics
tudies have been quite inconclusive for genotoxicity prediction;
hey nevertheless pointed to some genes, GADD45a (Hastwell
t al., 2006), p53R2 (Ohno et al., 2005), Ephx1,  Btg2, Cbr3 and Perp
Hendriks et al., 2011) of which a robust induction of expression
as noted for a series of genotoxins with apparently high sensitiv-
ty and speciﬁcity. There is a considerable interest in genes involved
n tissue development, cell death, cell-to-cell signaling, cell cycle
nd cellular growth, proliferation, DNA damage signaling and DNA
epair (Ellinger-Ziegelbauer et al., 2009; Jordan et al., 2010).
2.2.1.3.1. Response to p53 activation. The p53 tumor-
uppressor protein plays an important role by regulating the
xpression of a series of genes that promote genomic stabil-
ty, DNA repair, cell cycle arrest and induction of apoptosis in
he response to DNA damage (Levine, 1997; Nakamura, 2004).
hese genes include p53R2 (subunit of ribonucleotide reductase),
DKN1A (cyclin dependent kinase inhibitor 1A) and GADD45a
Growth arrest and DNA damage) (Corn and El-Deiry, 2007; Lu
t al., 2009).armacology 140 (2012) 492– 512 497
• p53R2 is activated by -ray, UV-irradiation and several genotoxic
compounds (Tanaka et al., 2000; Guittet et al., 2001; Xue et al.,
2003). A luciferase reporter plasmid dependent on three tandem
repeat sequences of the p53-binding site derived from the p53R2
gene has been developed for genotoxicity testing (Ohno et al.,
2005). This high-throughput assay is available for wild-type p53
human cell lines, is easy to conduct, requires only a small num-
ber of test samples and gives few false-positive data (Ohno et al.,
2008).
• GADD45a plays an important role in cell cycle control, DNA repair
mechanisms and signal transduction (Zhan, 2005). Other cellu-
lar signaling pathways, including BRCA1, c-MYC and NF-B are
implicated in GADD45a induction (Harkin et al., 1999; Barsyte-
Lovejoy et al., 2004; Zheng et al., 2005). GADD45a-dependent
reporter assays, based on green ﬂuorescent protein (GreenScreen
HC) or luciferase (BlueScreen HC), are commercially available for
testing genotoxicity response (Hastwell et al., 2006; Adler et al.,
2011).
2.2.1.3.2. Other pathways. Genes involved in cell cycle
(CDKN1A, GADD45, Cyclin E), apoptosis (BAX, BCL-XL), DNA repair
(XPC, DDB2, GADD45) and various physiological processes (FOS/JUN,
MDM2, FRA-1 IL-8, HSP70), which are found to be altered by ion-
izing radiation could be predictive biomarkers of genotoxicity
(Amundson et al., 2003; Snyder and Morgan, 2004).
2.2.1.4. Limitations of transcriptomics. Changes in genes expression
levels may  predict major changes in the proteins proﬁles in cells,
tissues or organisms but there are cases where a functional protein
is not produced despite gene expression; and so, changes in the
transcriptome do not necessarily reﬂect a change in the proﬁle of
“end-products” (Davies, 2010).
2.2.2. Proteomics
Proteomics is the study of a broad spectrum of proteins within a
cell or tissue, including proteins expression, structural status, func-
tional states and their interactions with other cellular components
(Kussmann et al., 2006; Wilson et al., in press). Key technologies rely
on two-dimensional gel electrophoresis coupled to mass spectrom-
etry (Merrick and Madenspacher, 2005; Ulrich-Merzenich et al.,
2007b), on antibody microarrays and on LC–MS–MS of proteins
fragments, a technique known as “shotgun proteomics” (Wolters
et al., 2001) and its speciﬁc platform variations, called ICAT (iso-
tope coding afﬁnity tags) and MuDPIT (multi-dimensional protein
identiﬁcation technology) (Yates, 2000). Afﬁnity chromatography,
ﬂuorescence resonance energy transfer and surface plasmon res-
onance are also used to identify protein–protein or protein–DNA
interactions. X-ray tomography is used to determine the location
of proteins or protein complexes in labeled cells (Ulrich-Merzenich
et al., 2007b).
Techniques are available but a large database of proteomics ‘ﬁn-
gerprint’ is still needed for compounds of known toxicity; once
available for a series of known carcinogens, it will be possible to
identify changes in biochemical pathways and to assess the toxic-
ity of unknown compounds. The products of the genes identiﬁed so
far in transcriptomics studies are probably promising candidates as
proteomics markers.
2.2.3. Metabonomics1 Metabolomics refer to the study of LMW  molecules within cells, whereas metabo-
nomics refer to a more systemic and complex change in tissues and body ﬂuids (Ekins
et al., 2005).
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his implies the quantitative and qualitative study of a wide range
f low molecular weight (LMW)  molecules produced as the net
esult of cellular functions (Lindon et al., 2004; van Ravenzwaay
t al., 2007; Youns et al., 2010) by nuclear magnetic resonance
NMR) spectroscopy, Fourier transform infrared and near-infrared
pectroscopy or mass spectrometry (MS). The latter technique
enerally requires pre-separation of the metabolic components by
as chromatography (GC), liquid chromatography (LC) or capillary
lectrophoresis (CE) (Tang and Wang, 2006; Lindon and Nicholson,
008; Arita, 2009). So far metabonomics have been scarcely
pplied to genotoxicity studies; major applications concern the
rinary proﬁling of damaged bases excreted upon DNA excision
epair and the search for activated metabolites of precarcinogens
Kirkland et al., 2005).
.3. Applications to herbal medicines
As genotoxicity testing aims to yield information on all types
f damage, including gene mutations, structural chromosome
berrations (clastogenicity) and numerical chromosome aberra-
ions (aneugenicity), standard test batteries have been developed
Kirkland et al., 2005) which include the assessment, with and
ithout metabolic activation, of (i) mutagenicity in a bacterial
everse mutation test (Ames test); and (ii) genotoxicity in mam-
alian cells in vitro and/or in vivo (ICH, 2008). These tests have
een developed for single chemicals and applying them to herbs has
een quite a challenge. The current EU guidelines for herbal prod-
cts (EMEA, 2007) deﬁne the Ames test as the primary endpoint
hat, if negative, accepts the drug as probably “non-genotoxic”.
his is not entirely satisfying however and there are still heavy
ebates on the topic (EMEA, 2008); indeed (i) the Ames test does
ot detect every genotoxic insult; and (ii) some common com-
ounds, including ﬂavonoids, yield very positive Ames tests but
re not carcinogens. Given the number of herbal products on the
arket and relatively low budgets available for research, there
re still relatively few herbs for which safety assessment accord-
ng to the current guidelines has been done. Nonetheless, some
erbal products and their secondary metabolites were assessed
or genotoxicity by various techniques. The Ames test has been
idely used to assess the mutagenicity of herbal products, includ-
ng for example extracts from Calendula ofﬁcinalis L., Echinodorus
acrophyllus (Kunth) Micheli, Mouriri pusa Gardner, Phyllantus
rbicularis Kunth, Punica granatum L., Parthenium hysterophorus L.
nd a green tea catechins preparation (Ramos et al., 1998, 2001;
anchez-Lamar et al., 2002; Santos et al., 2002; Nohynek et al.,
004). Among these extracts, Punica granatum whole fruit extract
nd the enriched fractions of ﬂavonoids and tannins from Mouriri
usa were found to give a positive genotoxic test. The genotoxi-
ity of Copaiba oil (Copaifera langsdorfﬁi Desf.) was demonstrated
y in vitro micronucleus and comet assays (Rao et al., 2006). The
linical toxicity and chemical identity of Guan MuTong was crit-
cally assessed with LC–MS conﬁrmation (Cheung et al., 2006).
etabonomics techniques have already been used in the tox-
city studies of Guan Mutong (Aristolochia manshuriensis Kom.)
Zhao et al., 2006a)  and its toxic component aristolochic acid (Jia
t al., 2006); aristolochic acid I was suggested to possess geno-
oxic potency also by QSAR modeling (Hashimoto et al., 1999;
rvidson et al., 2008; Chen et al., 2011b).  In the in vitro comet
ssay, artesunate, a semisynthetic derivative from artemisinin
Artemisia annua L.) induced DNA breakage in a dose-dependent
anner (Efferth et al., 2008). The transgenic rodent mutation
ssay has been used to assess the genotoxicity of phytochemicals
uch as riddelliine (pyrrolizidine alkaloid) (Ulrich-Merzenich et al.,
007a).
There is certainly a need for the development of validated meth-
ds to rapidly pinpoint indicators of genotoxicity that yield warningarmacology 140 (2012) 492– 512
signals and indicate which drugs need further assessment through
a complete test battery.
2.4. Applications to mushrooms
Whereas many mushrooms were shown to be non-genotoxic, a
number of investigations reported the mutagenic effects of mush-
room extracts (Sugimura, 2000). An example is agaritine from
Agaricus bisporus (J.E. Lange) Imbach, which is mutagenic, but
not genotoxic (Pool-Zobel et al., 1990). The carcinogenic, muta-
genic and teratogenic activity of 11 hydrazine analogues and
diazonium ions derived from 22 mushroom species have been
described (Toth, 1991). Remarkably, many of these mushrooms
are considered to be edible. In several cases, even protective
effects of mushrooms towards other genotoxic compounds have
been observed. For example, the culinary-medicinal Royal Sun
Agaricus (Agaricus brasiliensis S. Wasser et al.) revealed protec-
tive properties towards methyl methane sulfonate (MMS)  induced
mutagenicity and genotoxity in Drosophila melanogaster (Savic
et al., 2011); the Agaricus blazei Murrill mushroom protected
from cyclophosphamide-induced genotoxicity (Delmanto et al.,
2001).
Despite reports in the literature on lacking genotoxicity
potential of mushrooms, the potential hazard should not be under-
estimated. Mutagenicity and genotoxicity are frequently linked to
each other; it cannot be ruled out that a lack of genotoxic data is
due to technical reasons and that, with the advent of novel and
advanced techniques, the genotoxicity of more mushroom species
will be unraveled.
3. Part B: methods for teratogenicity assessment
The term “teratogens” refers to toxins that can lead to fetal death
or developmental abnormality; teratogenicity supposes a capacity
of a chemical to cross the placental barrier in sufﬁcient concentra-
tion to be active at a speciﬁc time in gestation (Wilson, 1977; Keeler,
1984). The baseline birth defects rate is about 6% (Christianson
et al., 2006) but varies considerably (2–8%) with respect to type of
defect, time, place, and other demographic, genetic, and environ-
mental factors (NRC, 2000; Levy et al., 2011); it is not known if this
baseline rate is a normal frequency of errors in the highly complex
developmental process or the consequence of as yet unidentiﬁed
environmental or dietary factors. Between 1 and 3% of all birth
defects are suggested to be attributable to chemicals and drugs,
but the ﬁgure is a rough estimation (Stummann et al., 2008). Major
identiﬁed teratogenic mechanisms rely on folate antagonism, neu-
ral crest cell disruption, endocrine disruption, oxidative stress,
vascular disruption and speciﬁc receptor- or enzyme-mediated ter-
atogenesis (Van et al., 2010). Although the literature details copious
lists of herbs that are supposedly contraindicated in pregnancy
(Lather et al., 2011), most herbal foods and medicines have never
been assessed and may  contribute to the supposedly baseline birth
defect rate. Table 1 compares the major methods developed for
teratogenicity assessment.
3.1. Conventional methods
The Organization for Economic Co-operation and Develop-
ment (OECD, 2012) and the European Centre for the Validation
of Alternative Methods (ECVAM, 2012) have largely investigated
the validation of teratogenicity tests; the FP6 European project
Reprotec has investigated possible strategies to cover the entire
mammalian reproductive cycle, resulting in a series of pub-
lished works that should be consulted for more details (Reprotec,
2012).
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Table 1
Comparison of methods for teratogenicity assessment.
Test Principle Speciﬁcity/Sensitivity Examples of tested herbs or natural
compounds
In vitro methods for teratogenicity assessment
Methods based on mammalian stem cells and embryos
Embryonic stem cell tests (ESC) Determination and evaluation
of three endpoints
(cytotoxicity assays on both
ESCs and 3T3 ﬁbroblasts; ECS
differentiation inhibition
assay)
Good reproducibility; overall
accuracy of 78% (Genschow
et al., 2004)
Validation data published
(Seiler and Spielmann, 2011)
Epimedium sp (the ﬂavonol icarriin
stimulates ESC differentiation in
cardiomyocytes) (Zhu et al., 2005)
Boehmeria nivea (L.) Gaud. (non
embryotoxic) (Tian et al., 2011a,b)
Mammalian micromass assay (MM)  Cells from the rat limb bud
(day 14 of gestation) are tested
for differentiation into
chondrocytes. Evaluation with
a chondrocyte speciﬁc dye
Overall accuracy of 70%
(Genschow et al., 2002)
Foeniculum vulgare L. (no
teratogenicity) (Ostad et al., 2004)
Mammalian whole embryo culture test (WEC) Embryos are isolated on day 10
of gestation and cultured for
48 h; morphological,
developmental, functional and
growth parameters are
measured
Overall accuracy of 80%
(Genschow et al., 2002)
Dihydroartemisinin primarily
affects primitive red blood cells,
causing subsequent tissue damage
and dysmorphogenesis (Longo
et al., 2006)
Methods based on embryos of lower order species
Frog embryo teratogenesis assay – Xenopus (FETAX) During the ﬁrst 96 h Xenopus
embryos development
parallels many of the major
processes of human
organogenesis
(Measurement of mortality,
malformation, and growth
inhibition)
Overall accuracy in predicting
teratogenic potential has been
claimed to be 79–83%
(Spielmann, 2005)
The test is considered not
sufﬁciently validated or
optimized for regulatory
applications (ICCVAM, 2000)
Teratogenicity shown for a
glycoalkaloid from Solanum
tuberosum (-chaconine)
(Friedman et al., 1991) and
artemisinin (Efferth et al., 2008;
Longo et al., 2008)
Fish  embryo toxicity test (FET) Zebraﬁsh embryos are
observed for 48 h for lethal and
sublethal endpoints
75% success rate in identifying
nonteratogenic compounds;
100% success rate in
identifying teratogenic
compounds (Ton et al., 2006)
The FET has been standardized
at the international level in
2007 (ISO 15088)
Flavonoids (Jones et al., 1964),
delta-9-tetrahydrocannabinol
(Thomas, 1975) and arecoline
(Chang et al., 2004)
In  vivo methods for teratogenicity assessment
Guidelines (OECD, 2012) Prenatal developmental
toxicity study
Two  generation reproduction
toxicity study
Reproductive/developmental
toxicity screening test
Repeated dose toxicity study
combined with the
reproductive/developmental
toxicity screening test
OECD test guideline TG 414
OECD test guideline TG 416
OECD test guideline TG 421
OECD test guideline TG 422
Mice Post-natal growth and viability Correct classiﬁcation of 83% of
tested chemicals (Chernoff and
Kavlock, 1982; Kavlock et al.,
1987)
Foetal and maternal adverse
effects: Psoralea corylifolia L.,
Ligusticum chuanxiong Hort.,
Scutellaria baicalensis Georgi (Tian,
2009)
No adverse effect: Boehmeria nivea
(L.) Gaud. () Tests of combinations
indicate protective interactions
(Tian, 2009)
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Molyneux et al., 2007; Cong et al., 2007, 2008). Ginsenoside Rb1.1.1. Characterization of compounds bearing structural alerts for
eratogenic effects
Epidemiological and experimental studies have shown that
ome medicinal plants (Lather et al., 2011) and their metabolites
xert teratogenic effects, notably alkaloids based on the struc-
ures (i) indolizidine (swainsonine induced vascular resistance,
asoconstriction and generalized stunting in the fetus of sheep
nd cattle (Lather et al., 2011)); (ii) pyrrolizidine (teratogens and
bortifacients (Prakash et al., 1999a)); (iii) piperidine (coniine,
-coniceine, anatabine and perhaps anabaseine caused congen-
tal contracture-type skeletal malformations and cleft palates,Panax ginseng C.A. Meyer caused
fetal gross malformation
(El-Ashmaoui et al., 2003)
restricted fetal movement, arthrogrypotic limb deformities in
calves); and (iv) triterpene (mammalian ingestion of jervane,
solanidane and spirosolane steroidal alkaloids produced cranio-
facial congenital malformations in offspring upon administration
during the primitive streak/neural plate developmental phase)
(Gafﬁeld and Keeler, 1994); cyclopamine, veratramine, veratro-
sine, and germine exerted teratogenic effects (Schep et al., 2006;(triterpenic saponine), extracted from Ginseng (a commonly used
worldwide herbal medicine) exerts direct teratogenic effects on rat
embryos (Chan et al., 2003).
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.1.1.1. Analytical methods. The detection of such compounds in
lant-based medicinal products could predict potential terato-
enicity. The analytical methods used to identify structural alerts
re similar as for genotoxins and include spectrophotometry, TLC,
C/MS and LC/MS–MS (Fu et al., 2002b, 2007; Napoli et al., 2010).
.1.1.2. In silico methods. The tools used are the same as for geno-
oxicity assessment, with similar limitations to their applicability
o complex mixtures such as herbal extracts. These include QSAR
nd expert systems; the previously mentioned TOPKAT and DEREK
ystems have long been used to analyze the teratogenic effects of
enobiotics (Dearden, 2003).
.1.2. In vitro methods for teratogenicity assessment
.1.2.1. Methods based on mammalian stem cells and embryos.
3.1.2.1.1. Embryonic stem cell tests (ESC tests or EST). The poten-
ial of embryonic stem cells (ESC) to differentiate into all cell types
f the mammalian organism (pluripotency) provides an impor-
ant tool to assess adverse effects on their differentiation, effects
hat might be relevant for in vivo embryotoxicity. Taking into
ccount that general cytotoxicity is a critical parameter for iden-
ifying embryotoxicants (Stummann et al., 2008), ESC tests are
ased on three endpoints, i.e. differentiation inhibition of ESC
nd cytotoxicity (often by the MTT  (3-(4,5-dimethyl-2-thiazolyl)-
,5-diphenyl-2H-tetrazolium bromide) assay) of both ESC and
broblasts (Balls and Hellsten, 2002; Stummann et al., 2008). ESC
ests differ in their readouts but also in the differentiated target cells
zur Nieden et al., 2004; Peters et al., 2008); neural cells (Stummann
t al., 2009; Theunissen et al., 2010), cardiomyocytes (Buesen et al.,
009), skeletal cells (zur Nieden et al., 2004, 2010; Stummann et al.,
009) and endothelial cells (Fukushima et al., 2010) are most often
nvestigated. The in vitro differentiation into cardiomyocytes has
een extensively used due to the easy visual identiﬁcation of con-
racting cells in differentiated ESC cultures (van Dartel et al., 2009).
rieﬂy, ESCs are cultivated in hanging drops in cell culture medium
ithout LIF (leukemia inhibitory factor) to induce the formation of
ell multicellular aggregates (“embryoid bodies”); these are further
ultured in suspension until day 3, plated on day 5 and assessed
y light microscopy on day 10 for the number of embryoid bodies
ontaining beating areas, normalizing versus a negative control (dif-
erentiation level in control must be over 87.5%) (Stummann et al.,
008). Human ESCs (derived from the inner cell mass of blastocysts)
re generally used (Thomson et al., 1998); being more speciﬁc to the
uman response than cells from surrogate species (e.g. rat, mouse)
hey may  generate more reliable in vitro prediction endpoints (West
t al., 2010). Nevertheless the use of non-human embryonic stem
ells has been approved by the European Centre for the Valida-
ion of Alternative Methods (ECVAM) (Genschow et al., 2002). The
imitations of ESC tests are the relatively long culture duration,
he subjective and laborious endpoint scoring and the so far lim-
ted characterization of its applicability domain and predictability
Marx-Stoelting et al., 2009).
3.1.2.1.2. Mammalian micromass test (MM  test). This test is
ased on the ability of a xenobiotic to inhibit differentiation of
mbryonic tissue cells in the absence of cell death; the test is sup-
osed to reﬂect an in vivo teratogenic potential (Hansen and Abbott,
009). A limb bud or the cephalic tissue of mid-organogenesis
at embryo (Adler et al., 2011) is dissociated into a single cells
uspension. These cells, placed into culture in small volumes at
igh density, replicate, migrate, re-aggregate, and differentiate
nto a speciﬁc cell type, forming numerous small foci of differ-
ntiating cells without additional stimulation (Flint, 1993; Adler
t al., 2011). The cell viability and differentiation are measured by
taining with neutral red and a stain speciﬁc of chondrocytes or
eurons, respectively (Brown et al., 1995). The test based on limb
uds is an attractive teratogenic model as it reproduces cartilagearmacology 140 (2012) 492– 512
histogenesis, a fundamental step in skeleton morphogenesis, and
the protocol has been validated by ECVAM (Genschow et al., 2002).
3.1.2.1.3. Mammalian whole embryo culture test (WEC tests).
For the post-implantation whole embryo culture (WEC) test, mam-
malian (rat or mouse) embryos are maintained in culture for short
periods throughout the phase from fertilization to the end of
organogenesis. This allows probing major aspects of organogenesis,
including heart development, closure of the neural tube, devel-
opment of ear and eye, brachial bars and limb buds; disturbance
during this period may  lead to general retardation of growth and
development or to speciﬁc malformations in one or several organs
(Brown et al., 1995; Spielmann, 2005). Drug-metabolizing enzymes
can be incorporated and concentrations of tested compounds and
metabolites can easily be monitored in the culture medium and
in embryonic tissues (Bechter et al., 1991). Mouse or rat embryos
with 2–5 somites are explanted from the uterus, cultured (Piersma
et al., 2004; Paniagua-Castro et al., 2008; de Jong et al., 2011) and
exposed to various concentrations of the tested compounds. The
morphology of the embryos is carefully assessed and a series of
endpoints are scored, including the yolk sac diameter, crown-rump
length and head length. Total embryonic protein increases loga-
rithmically with embryonic age and is considered to be the most
suitable measure of embryonic growth (Brown and Fabro, 1981;
Paniagua-Castro et al., 2008; Piersma et al., 2008). The protocol has
been validated by ECVAM (Genschow et al., 2002).
3.1.2.1.4. Comparison of tests on mammalian material. Studies
of 20 compounds in a test panel reported that the WEC  test shows
the best concordance between in vivo classiﬁcation and in vitro
test results with 80% correct classiﬁcations versus 78% for the ESC
test and 70% for the mammalian micromass test (Genschow et al.,
2002). The WEC  model mirrors the complexity of the embryogene-
sis closely, although it is laborious, animal consuming and limited
to a speciﬁc window of embryonic development (Stummann et al.,
2008); it allows the objective quantiﬁcation of both growth and
differentiation, and consequently differences between general tox-
icity and teratogenic effects can be seen (Hewitt et al., 2005). The
MM test is much faster, but includes only differentiation of chon-
drocytes as toxicological endpoint (Stummann et al., 2008). The ESC
test is presently the only in vitro test based on a cell line that has
undergone a formal validation trial (Bremer et al., 2005; Stummann
et al., 2008). However, all tests require the sacriﬁce of pregnant
mammals for harvesting early embryos (Selderslaghs et al., 2009).
3.1.2.2. Embryos of lower order species test. According to regula-
tory guidelines, developing drugs for administration to pregnant
women  must be tested for teratogenic potential in a rodent and
non-rodent mammalian species (Van den Bulck et al., 2011). How-
ever, low vertebrate animal models (anuran amphibian, zebraﬁsh,
chick) are increasingly proposed as alternatives to mammals
to assess teratogenicity of xenobiotics. One of the reasons is
that embryogenesis is highly conserved across amphibians and
mammals, with similarities at the phylotypic stage at both morpho-
logical and molecular levels (Di Renzo et al., 2011). Furthermore,
use of lower order species is in line with the current trend of
applying the 3Rs principle (reﬁnement, reduction, replacement) in
reducing the number of animals necessary for an evaluation (Van
den Bulck et al., 2011).
3.1.2.2.1. The frog embryo teratogenesis assay-Xenopus (FETAX).
Xenopus laevis is one of the most used models for vertebrate exper-
imental embryology due to its aquatic development, large eggs,
easily manipulated embryos, low cost, reliability and reproducibil-
ity (Richards and Cole, 2006). It has been suggested as an alternative
screening model for developmental toxicity purposes (Mouche
et al., 2011). Xenopus tropicalis, highly related to Xenopus laevis,
presents the advantages of a smaller size and shorter life cycle
(Shi et al., 2010). Breeding is induced by subcutaneous injection
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f human chorionic gonadotrophin in the dorsal lymph sac of both
ales and females. Adults are removed on the second morning after
he injection, the embryos are harvested without removing their
elly coats, cultured and exposed to chemicals. At the end of the
est, embryos are evaluated for mortality (absence of heartbeat) and
he surviving embryos are anaesthetized and ﬁxed with formalin.
xamination under a dissecting microscope allows measurement of
ody length and assessment of malformations number and types
Shi et al., 2010; Di Renzo et al., 2011). This test has been evaluated
y the U.S. Interagency Coordinating Committee on the validation
f alternative methods who however concluded that FETAX was
ot sufﬁciently validated or optimized for regulatory applications
ICCVAM). The assay is limited by the aqueous solubility of test sub-
tances; its overall accuracy in predicting teratogenic potential has
een claimed to be 79–83% (Selderslaghs et al., 2009).
3.1.2.2.2. Fish embryo toxicity test (FET). The vast majority of
nformation to support the use and interpretation of the FET has
een generated on the zebraﬁsh, Danio rerio (Lammer et al., 2009;
elderslaghs et al., 2009; Van den Bulck et al., 2011). Less robust
ata sets exist for other species, particularly those of interest to
sia (Oryzias latipes)  and North America (Pimephales promelas)
Braunbeck et al., 2005).
The zebraﬁsh, a small freshwater ﬁsh (3 cm)  offers several
dvantages for teratogenicity assessment including economic
usbandry requirements, high fecundity and rapid ex utero devel-
pment (Hill et al., 2005; Avanesian et al., 2009). The eggs remain
ransparent from fertilization up to and beyond pharyngulation
hen the tissues become dense and pigmentation is initiated.
his allows observation of the main morphological changes dur-
ng earlier developmental stages. Moreover, zebraﬁsh embryos
hat are malformed, lack organs, or display organ dysfunction can
sually survive well beyond the time at which those organs nor-
ally start to function in healthy individuals (Hill et al., 2005).
ebraﬁsh embryos can activate proteratogenic/procarcinogenic
ubstances without any addition of exogenous metabolic activa-
ion systems as they present phase I enzyme activities at very
arly stages of development (Weigt et al., 2011). Endpoints used
or assessing the effects of tested compound include embryo mor-
ality, yolk sac edema, tail malformation, changes in hatching
ates and deﬁciencies in gastrulation, somite formation, head for-
ation, heartbeat and pigmentation (Oliveira et al., 2009; Van
en Bulck et al., 2011). Zebraﬁsh embryo toxicity test presents
 75% success rate in identifying nonteratogenic compounds
nd a 100% success rate in identifying teratogenic compounds
Ton et al., 2006).
3.1.2.2.3. Chick embryo toxicity test. Avian embryos have rarely
een used for embryotoxicity testing. The results obtained on
hicks were disappointing as this test cannot distinguish general
oxicity from speciﬁc developmental effects (Jelinek et al., 1985;
rown et al., 1995).
.1.2.3. Utility of in vitro methods. Although in vitro models pro-
ide valuable teratogenicity data, they cover all of the aspects of
renatal development; they also lack a placenta, which offers some
rotection for the developing organism in mammals, and so cannot
etermine the real fetal exposure (Avanesian et al., 2009; Van den
ulck et al., 2011). None of these in vitro methods can currently be
egarded as a full replacement for existing in vivo studies; however
hey can be considered as a pre-screen strategy to prioritize xeno-
iotics for in vivo assessment, reducing and optimizing animal use
n teratogenicity evaluation..1.3. In vivo methods for teratogenicity assessment
In vivo teratogenicity assessments are generally based on stud-
es in rats, mice, rabbits, and even in monkeys. Pregnant females
eceive the tested compounds and throughout the experimentalarmacology 140 (2012) 492– 512 501
period are weighed and examined for signs of toxicity. At differ-
ent time points, females are euthanized and a series of parameters
in the uterus (including fetus), ovaries and placenta are exam-
ined, including number of corpora lutea, number of implantation
sites, number of early and late resorption, number of live and
dead fetuses, sex of the fetuses, number of malformed fetuses and
types of external abnormalities (exencephaly, cleft palate, abdom-
inal hernia, polydactly, open eyelid, etc.), weight of ovaries, weight
of uterus containing placentas and fetuses, weight of empty uterus,
weight of fetuses, weight of the placentas, gross evaluation of the
placentas. Half of the fetuses are examined for soft tissue abnor-
malities and the remaining half for skeletal abnormalities (Favero
et al., 2005; Tian et al., 2005; Wangikar et al., 2005; Grifﬁths
et al., 2007). Cynomolgus monkeys (Macaca fascicularis)  have been
sometimes used in the teratogenicity assessment of xenobiotics
(Hendrickx et al., 2000; Ema  et al., 2007). Indeed, earlier stud-
ies demonstrated that embryonic development in this non-human
primate very closely parallels that of human embryos (Hummler
et al., 1990). The principle of teratogenicity assessment is identical
except terminal cesarean sectioning is performed under anesthesia
to recover fetuses (Ema  et al., 2007).
The use of more than one species for testing is widely regarded
as necessary because it increases chance to detect agents that may
be teratogenic for humans. Typical guidelines recommend using
two  species, mostly rat and rabbit. The former is used because
toxicity data are commonly obtained with this species; the lat-
ter because it has somewhat different placentation and pregnancy
physiology than rodents, but also for historical reasons. Rabbits,
but not rats, showed limb-reduction and deformities when they
received thalidomide (Barlow et al., 2002).
3.2. Current “omics” approaches for predicting teratogenicity
Since toxicological testing with animals is expensive and time
consuming and raises serious ethical issues, there is an urgent need
to develop alternative or complementary models to support the 3Rs
principle in animal testing. Reproductive medicine is now entering
the exciting era of the “omics” (Scott and Treff, 2010); the use of
these techniques in teratology is still in its infancy but their advent
has added further impetus to the development of alternatives to
in vivo toxicity testing (Bhogal et al., 2005; Luijten et al., 2010).
At least 17 signaling pathways have been described during fetal
development with their speciﬁc periods of activity; six of these are
known to be crucial for early development in most animals, while
four are more used in late development (NRC, 2000; Stummann
et al., 2008). Study of these pathways important steps by “omics”
methods in animal or cell models may  give important clues to ter-
atogenic agents and allow developing high-throughput tests for
teratogenicity alert signals.
3.2.1. Transcriptomics
The incorporation of transcriptomics in established tests is
expected to provide more informative and improved endpoints as
compared with morphology, allowing early detection of differenti-
ation modulation (Kultima et al., 2010; van Dartel et al., 2010; van
Dartel and Piersma, 2011).
3.2.1.1. Application to embryonic stem cell tests (ESC tests). The very
ﬁrst studies that evaluated gene expression regulation as a conse-
quence of xenobiotics exposure in the ESC test were based on the
selection of well-known developmental markers (Myh6 and Myh7)
and showed that endpoint objectivation could be obtained through
gene expression analysis (Bigot et al., 1999). In order to better
understand the molecular mechanisms of teratogenesis, embry-
onic zebraﬁsh cells were exposed to xenobiotics, and changes in
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ranscript expression were analyzed by microarrays (Fent and
umpter, 2011).
.2.1.2. Application to mammalian whole embryo culture tests (WEC
ests). Late occurring malformations (e.g. cleft palate) cannot be
etected morphologically in this test due to the limited period
f observation (48 h), but gene expression changes occurring dur-
ng this period may  be early predictors for malformations that
ecome morphologically visible only later in embryonic/fetal gen-
sis. Transcriptomics have successfully employed for monitoring
arly responses in the Hoxb1 gene expression in whole embry-
nic culture after exposure to the embryotoxicant retinoic acid (RA)
Morriss-Kay et al., 1991; Zhang et al., 2003; Menegola et al., 2004).
fterwards, the expression levels of 14 known RA-responsive genes
ould be measured in whole embryo by real-time quantitative PCR;
hese genes (A2m, Afp,  Bmp4, Cdkn1a, Cdx2, Dbccr1,  Egr2, Hoxa1,
tx1, Pmp22,  Pms1, Shh, Shox2 and Otx2) encode factors, whose
egulation can stimulate aberrant tissue differentiation and mor-
hogenesis (Rogers et al., 1997; Luijten et al., 2010).
.2.1.3. Application to in vivo tests. In addition to prediction, tran-
criptomics studies can also help to understand the molecular
echanisms underlying teratogenicity. For example, analysis of
he embryonic messenger RNA following administration of thalido-
ide to pregnant Cynomolgus monkeys has now identiﬁed many
ey pathways implicated in thalidomide embryopathy (Simoniello
t al., 2011).
.2.2. Proteomics
The applications of proteomics in teratogenicity testing seem
ery limited (Hansen and Abbott, 2009). To the best of our knowl-
dge, no studies have been published so far.
.2.3. Metabonomics
Proﬁling human embryonic stem cells for their secreted metabo-
ites has been proposed as an alternative testing platform for
ssessing embryonic/fetal toxicity of compounds (Cezar et al., 2007;
est et al., 2010). Metabonomics were notably able to detect
ifferences in response to valproate, revealing novel biochemical
athways of injury that were in agreement with data from previous
n vivo valproate studies (West et al., 2010).
.3. Applications to herbal medicines
To the best of our knowledge, teratogenicity of herbal medicines
as not been assessed with the help of “omics” technologies. Con-
entional in vitro and in vivo methods have been used to evaluate
eratogenicity potency of herbal products. Boehmeria nivea aque-
us extract at 32 g/kg/day did not cause signiﬁcant embryotoxicity
r maternal toxicity in mice, although it might cause cytotoxic-
ty in cultured embryonic stem cells (ESC test) at a higher dose
Huang et al., 2006; Tian et al., 2011a,b). An evaluation of the ter-
togenicity of Foeniculum vulgare L. essential oil on the rat embryo
imb bud culture (mammalian micromass test) showed no evidence
f teratogenicity (Ostad et al., 2004). Artemisinin was  found posi-
ive for teratogenicity on a Xenopus assay (FETAX) (Efferth et al.,
008; Longo et al., 2008); its derivative dihydroartemisinin has
een shown in a rat WEC  model to primarily affect primitive red
lood cells, causing subsequent tissue damage and dysmorphogen-
sis (Longo et al., 2006). The Zebraﬁsh embryo toxicity test has
lready been used to evaluate the teratogenicity of several natural
roducts consumed by humans, including various ﬂavonoids (Jones
t al., 1964), delta-9-tetrahydrocannabinol, the major psychoactive
onstituent of marijuana (Thomas, 1975) and arecoline, the major
lkaloid in betel nuts (Chang et al., 2004). In vivo treatment of preg-
ant mice with ginseng (Panax ginseng C.A. Meyer) caused fetalarmacology 140 (2012) 492– 512
gross malformation especially when taken for an extended time
during pregnancy (El-Ashmaoui et al., 2003).
3.4. Applications to mushrooms
It is known that ribosome-inactivating proteins (RIP) of plants
can hamper embryonic development in mice. Recently, a similar
effect has been shown for two  mushroom RIPs, (i) lyophyllin from
Lyophyllum shimeji (Kawam.) Hongo that also provokes embryonic
abnormalities in mice (cranial neural tube, forelimb buds, branchial
arches and body axis); at high concentrations, forebrain blisters
appeared within the cranial mesenchyme (Chan et al., 2010); and
(ii) hypsin from Hypsizigus marmoreus Bunashimeji. In contrast,
another RIP, velutin from Flammulina velutipes (Curt.:Fr.) Sing. did
not exert any adverse inﬂuence on mouse development, indicat-
ing that teratogenicity is not a general feature of all RIPs (Ng et al.,
2010).
4. Part C: methods for nephrotoxicity assessment
Nephrotoxicity deﬁned as a renal disease or dysfunction, is
often caused by drugs, chemicals, industrial or environmental toxic
agents. Factors contributing to the nephrotoxicity of herbal prod-
ucts may  be related to an intrinsic toxicity of plant constituents
and ingredients or secondary metabolites, to a contamination of
the product itself by other nephrotoxic agents, to misidentiﬁca-
tion of medicinal herbs or overdose (Zhao et al., 2006b; De Smet,
2007; Lai et al., 2009). Drug-induced renal dysfunction is frequent
in clinical practice. Kidneys are particularly vulnerable to drug tox-
icity because they are highly vascularized and play a major role
in metabolism and elimination of toxicants (Karie et al., 2010). In
this section, we will focus on applicable methods in assessing drug
renal toxicity and discuss advantages and disadvantages of each
method. In silico methods have also been applied to nephrotoxicity
studies (Wolfgang and Johnson, 2002; Ursem et al., 2009) and some
structural alerts are known such as aristolochic acids (Fang et al.,
2011), ochratoxin A (Sieber et al., 2009) or the diterpen triptolide
(Xia et al., 2009).
4.1. Review of applicable methods to test and evaluate herbal
renal toxicity
4.1.1. In vivo animal models
Animal models represent the “gold standard” (de Broe and
Porter, 2008) of toxicity assessment and are recommended by
the European Medicines Agency (EMA) and the Food and Drug
Administration (FDA) for investigating toxicity of new drugs. Acute,
sub-acute and chronic toxicities are classically assessed in two
animal species (one rodent and one non-rodent). However, these
models are expensive and time consuming; therefore it is not prac-
tical to use them for screening the nephrotoxicity of a large number
of samples. Moreover, extensive use of animals for toxicity assess-
ment is not in line with the current trend of applying the 3Rs
principle (Van den Bulck et al., 2011).
In brief, animals are treated with the tested compounds, and
then biomarkers of nephrotoxicity are measured in urine or blood
samples and kidneys are harvested for histological analyses.
However, utilization of classical markers of kidney injury (pro-
teinuria, plasma creatinine and blood urea nitrogen (BUN)) in
nephrotoxicological studies is limited. Indeed, because of the great
ability of the kidneys to compensate renal mass loss and to recover
after acute insult, the sensitivity of serum creatinine and BUN is
very poor. It has been observed that a reduction of renal function-
ality occurs only after approximately two thirds of renal biomass
has been lost. In addition, these markers lack speciﬁcity. Indeed,
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he serum level of creatinine, a breakdown product of muscle tis-
ue, depends on age, gender, muscle mass, and weight. It has also
een reported that gastrointestinal bleeding or enhanced protein
atabolism and other pathologic conditions can lead to an increase
n serum BUN without any negative impact on the kidneys.
Recently, new biomarkers have been described and are con-
idered as promising candidates to detect acute or chronic
ubulotoxicity (Hoffmann et al., 2010b; Marrer and Dieterle, 2010)
nd are summarized in Table 2. Several studies have compared
hese markers with plasma creatinine and BUN and have demon-
trated their superiority (more sensitive and more speciﬁc). These
arkers have therefore been accepted by FDA and EMA  for the
etection of acute kidney injury in the context of non clinical drug
evelopment. However, if these biomarkers seem to be promising,
ata regarding screening toxicological studies are limited, as only
able 2
xperimental support for urinary biomarker candidates as indicators of kidney injury. (PT
isease.)
Marker Comments Presum
Calbindin Vitamin D-dependent calcium binding protein
expressed in the distal tubule/collecting duct:
mediates uptake of Ca2+ from urine
DT dam
Clusterin Secreted glycoprotein expressed in a wide
range of tissues;
Extracellular chaperone implicated in cell
adhesion, tissue remodeling, membrane
re-cycling, cell cycle regulation, DNA repair,
and apoptosis
PT + DT
Cystatin C Extracellular cysteine proteinase inhibitor
expressed and produced by most nucleated
cells;
Freely ﬁltered from blood through the
glomerulus, then reabsorbed and degraded by
proximal tubule cells
PT dam
GST-  Cytosolic phase-II biotransformation enzyme
involved in detoxiﬁcation of a wide range of
xenobiotics
PT dam
KIM-1  Kidney injury molecule 1
Transmembrane protein expressed by tubule
epithelial cells in response to injury
Acts as a phosphatidylserine receptor and
confers phagocytic capacity to clear cell debris
PT dam
NGAL/lipocalin-2 Neutrophil gelatinase-associated lipocalin
Acute-phase protein initially found in
activated neutrophils but also expressed by a
wide range of tissues in response to injury
Participates in host innate immune defence by
binding bacterial siderophores to limit
bacterial iron acquisition;
Glomerular ﬁltration and reabsorption by
proximal tubule cells
T dam
2-Microglobulin Protein found on the surfaces of all nucleated
cells, shed into blood;
Glomerular ﬁltration and reabsorption by
proximal tubule cells
PT dam
Osteopontin Secreted phosphoprotein, extracellular
structural protein which interacts with
multiple cell surface receptors;
Role in immune function, chemotoxis, bone
remodeling and apoptosis
PT + DT
Timp-1 Tissue inhibitor of matrix metalloproteinase 1
Regulates extracellular matrix synthesis and
degradation;
Promotes tubulointerstitial ﬁbrosis through
inhibition of proteolytic matrix
metalloproteinases;
Exacerbates inﬂammation and renal scaring
PT dam
VEGF  Vascular endothelial growth factor
Induced endothelial cell proliferation and
angiogenesis, promotes cell migration,
enhances vascular permeability
T dam
dapted from Hoffmann et al. (2010b).armacology 140 (2012) 492– 512 503
few studies have compared these markers with the gold standard
(histopathological analyses) (Hoffmann et al., 2010b; Tonomura
et al., 2010). Therefore, from our point of view, biomarkers should
not be used alone to assess nephrotoxicity of TCM.
4.1.2. Isolated perfused kidney
Isolated perfused kidney from rat and mouse (de Broe and
Porter, 2008) is ideal for pathophysiologic studies (such as renal
vascular, tubular and glomerular functions). It can be also used
to evaluate chemicals for their potential nephrotoxicity (Gandolﬁ
and Brendel, 1990). Since the isolated perfused kidney is an intact
organ and maintains structural integrity, it can reproduce the in vivo
toxicity for very acute toxicants (Shanley et al., 1986). However,
this system represents a difﬁcult technique, suffers from limited
viability and is time consuming.
: proximal tubule; DT: distal tubule; AKI: acute kidney injury; CKD: chronic kidney
ed marker of Experimental support
age –
 damage Increased following renal ischemia, unilateral urethral
obstruction or in response to various nephrotoxins, e.g.
increased mRNA expression in kidneys of rats treated with
gentamicin, ochratoxin A, sevoﬂurane, cisplatin,
vancomycin, bacitracin
age Cystatin C is considered as a better predictor than serum
creatinine for glomerular function in CKD
A  50% increase in cystatin C can predict AKI 48 h before the
rise  in serum creatinine and before creatinine clearance
reduction
Increased in diabetic rats and in response to subtotal or
unilateral nephrectomy;
Elevated during chromium nephropathy
age Increased urinary excretion in response to cadmium,
ﬂuoride, aristolochic acid; altered mRNA expression in
response to a range of nephrotoxicants
age Elevated in response to gentamicin, mercury, chromium,
cadmium;
Increased mRNA expression in kidneys of rats treated with
gentamicin, ochratoxin A, sevoﬂurane, cisplatin,
vancomycin, bacitracin
age Increased in response to gentamicin nephrotoxicity
increased mRNA expression in kidneys of rats treated with
gentamicin, ochratoxin A, cisplatin, vancomycin, bacitracin
age Increased urinary excretion in response to ochratoxin A,
depleted uranium, ifosfamide, chlorotriﬂuoroethylene,
1,1-dichloro-2,2-diﬂuoroethylene
 damage Increased mRNA expression in kidneys of rats treated with
gentamicin, ochratoxin A, sevoﬂurane, cisplatin,
vancomycin, bacitracin
age Increase in rodent model of gentamicin nephrotoxicity;
Increased mRNA expression in kidneys of rats treated with
gentamicin, ochratoxin A, sevoﬂurane, cisplatin,
vancomycin, bacitracin
age Increased expression in response to cyclosporin A and
tacrolimus mediated nephrotoxicity
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.1.3. Renal cell culture models
Renal cell culture models (de Broe and Porter, 2008) have been
sed for a long time. Two models of renal cell culture are available:
ell lines and primary cell cultures. Cell lines offer several advan-
ages (easier to culture, unlimited life span, no isolation procedure
nd better stability) but are probably more distant from in vivo
ituation than primary cells. Several renal cell lines reproducing dif-
erent renal cell types are available: cell lines with characteristics
f the proximal tubule such as normal rat kidney cells (NRK52E),
ewis lung carcinoma porcine kidney (LLC-PK1), opossum kidney
OK) or human kidney-2 (HK-2 cells), generated by transduction of
uman primary proximal tubular cells with human papilloma virus
HPV); cell lines with characteristics of the distal tubule or the col-
ecting duct such as Madin Darby canine kidney cells (MDCK) or
adin Darby bovine kidney cells (MDBK). Primary renal proximal
ubular epithelial cells (RPTEC) share more similarities to in vivo
ells. However, the isolation procedure and the limited access to
hese cells, particularly those from human source, hamper their
tilization. Moreover, primary cell lines have a limited life span
nd their phenotype can change rapidly due to different culture
onditions (no standard culture condition is available in the liter-
ture). Renal cell culture models offer a better way to understand
iochemical and cellular mechanisms of cytotoxicity, are cheaper
nd less time consuming than animal experimentation. However,
he nephrotoxic potency of a xenobiotic will/may depend on the
ephron segments and the cell types: the epithelial cells from the
roximal tubule are usual targets of toxic injury.
These methods do not allow studies related to absorption, dis-
ribution, metabolism and elimination (ADME). In vitro toxicity
tudies on metabolites are indeed unfeasible as metabolic path-
ays are not previously described.
.1.4. Renal slice models
Contrasting with hepatotoxicity studies, only few renal slice
odels were used to study nephrotoxicity related to iodinated
ontrast compounds, cisplatin, sevoﬂurane (Catania et al., 2001;
ickers and Fisher, 2004; Vickers et al., 2004; Harmon et al., 2009).
elective injury has been observed following in vitro nephrotox-
cant exposure to precision-cut renal slices (Ruegg, 1994). Renal
ortical slices are generally prepared from kidneys of untreated
ats and incubated with tested compound or vehicle for 2 h. At
he end of the 2 h incubation, tissue gluconeogenesis capacity
pyruvate-stimulated gluconeogenesis) and lactate dehydrogenase
LDH) release are determined as measures of cellular function and
ytotoxicity (Hong et al., 2002). This model provides interaction
etween various cells within the nephron and has proven to be
 useful in vitro system for biotransformation and toxicity studies
Gandolﬁ et al., 1995; Minigh and Valentovic, 2003); however, it is
ot useful to assess chronic renal toxicity.
.1.5. “Omics” technologies
“Omics” technologies have the potential for the development
f molecular markers hopefully allowing for detection of early
hanges in signal transduction, regulation and biochemistry with
igh sensitivity and speciﬁcity.
.1.5.1. Transcriptomics. Several studies have analyzed transcrip-
ome changes following acute kidney injury in toxic kidney injury
odels. In their study Ozaki et al. found that hundreds of genes
ere found to be deregulated in a model of gentamicin acute kidney
njury (Ozaki et al., 2010). The gene with the most prominent up-
egulation was the kidney injury molecule-1 (Kim-1) (also known
s HAVCR1 gene). In another study, Rokushima et al. analyzed tran-
criptome proﬁle following cephalosporin intoxication and found
undreds of genes to be deregulated (Rokushima et al., 2008).
mong these, Kim-1 was the most quantitatively upregulated. Inarmacology 140 (2012) 492– 512
addition, several studies have also demonstrated renal expres-
sion changes of genes encoding acute kidney injury biomarkers in
response to injury induced by a variety of nephrotoxicants: Kim-
1, metallopeptidase inhibitor 1 (TIMP1), clusterin, osteopontin,
and neutrophil gelatinase-associated lipocalin/lipocalin 2 (NGAL)
(Ichimura et al., 2004; Rached et al., 2008; Wang et al., 2008; Zhou
et al., 2008; Kondo et al., 2009).
4.1.5.2. Proteomics. “Proteomics” technologies were used for qual-
itative and quantitative assessment of urinary protein modulation
associated with toxicants exposure in rats. Samples are analyzed
using two complementary analysis techniques: (i) bi-dimensional
(2-DE) electrophoresis followed by mass ﬁngerprinting (MALDI-
TOF) identiﬁcation; (ii) analysis of protein gels (SDS–PAGE)
separation followed by (LC–MS/MS) and the use of spectral count-
ing as a semi-quantitative tool to identify proteins that change in
abundance (Mueller et al., 2008).
4.1.5.3. Metabonomics. Urinary 1H NMR  spectral-based
metabolomics is a new approach for determining changes in
endogenous metabolites in animals exposed to nephrotoxic agents
(Kim et al., 2010; Zhang et al., 2012). For example, urinary 1H
NMR  spectroscopy revealed apparent differential clustering of
metabolites between the control and HgCl2 (nephrotoxic agent)
treatment groups as evidenced by principal component analysis
(PCA) and partial least square (PLS)-discriminant analysis (DA).
In HgCl2-treated rats, the concentrations of endogenous urinary
metabolites of glucose, acetate, alanine, lactate, succinate and
ethanol were signiﬁcantly increased, whereas the concentrations
of 2-oxoglutarate, allantoin, citrate, formate, taurine, and hip-
purate were signiﬁcantly decreased (Kim et al., 2010). 1H NMR
urinalysis could be used to predict or screen nephrotoxic potency
of herbal medicinal products.
4.2. Comparisons of screening methods for herbal kidney toxicity
No study has directly compared these different methods of
kidney toxicity screening. To date, the animal model is still the
gold standard. In addition, the recent development of acute kidney
injury biomarkers has strongly enhanced the sensitivity of early
renal lesions detection. In a recent publication, Hoffman et al. eval-
uated and compared novel kidney biomarkers in preclinical toxicity
studies (Hoffmann et al., 2010a).  Interestingly, they demonstrated
that Kim-1 (AUC = 0.99) and clusterin (AUC = 0.93) were sensitive
and early expressed, even before histologically proven lesions in
several animals. However, the toxicants tested in this study were
all speciﬁc for the proximal tubule and none of them was speciﬁc for
any other part of the nephron. In another study published by Rouse
et al. (2011),  several kidney injury biomarkers were evaluated in a
gentamicin rat model. Overall, the quickest and largest response to
gentamicin-induced injury concerned Kim-1 biomarker.
In addition to the classical new kidney injury biomarkers, sev-
eral urinary markers have been identiﬁed with ‘omics’ methods.
However, they were rarely compared to other toxicological screen-
ing approaches and they were not prospectively validated. A ﬁrst
review published in 2005 (Gibbs, 2005) evaluated the relative sen-
sitivity and speciﬁcity of proteomics and metabonomics techniques
compared with traditional techniques for assessing xenobiotic
induced nephrotoxicity. The authors concluded that there was  no
consistent evidence that the novel methodologies were any more
sensitive than the traditional methods for assessing nephrotoxicity.
Another study (Ebbels et al., 2007) recently published by the COMET
group (consortium for metabolic toxicology) was performed to
build a model for toxicity prediction using a set of 80 toxics. Unfor-
tunately, the sensitivity for kidney toxicity was only 41% (with a
speciﬁcity of 100%). To conclude, these techniques are certainly
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elpful to detect new biomarkers of renal injury but, considering
he lack of validation, they should be regarded as complemen-
ary tools to detect renal injury in a screening program (Devarajan,
008; Beger et al., 2010; Rouse et al., 2011).
.3. Applications of screening methods to herbal medicines
Almost all the above described methods have been used to
ssess nephrotoxicity of several TCM products. However, they were
ot applied in screening purposes and no prospective validation is
vailable up to now.
To our knowledge, renal cells culture models have been mainly
sed in aristolochic acids models. A series of aristolochic acid
erivatives isolated from Aristolochia spp were analyzed for their
ephrotoxic potential using the neutral red dye exclusion assay
n cultures of renal epithelial cells (Balachandran et al., 2005). In
ddition, a recent study has investigated renal toxicity of 47 herbs
raditionally used for kidney and urinary disorders in two cell lines
odels (Wojcikowski et al., 2009).
Renal slice models have also been used in investigating AA and
ripterygium toxicity (Dan et al., 2008; Dickman et al., 2011).
Besides nephrotoxicological studies on cisplatine, ciclosporine,
iCl2 and indomethacin, metabolomics and proteomics have been
lso used to investigate TCM nephrotoxicoly, e.g. Aristolochia man-
huriensis Kom. (Chen et al., 2006; Zhang et al., 2006; Chan
t al., 2008; Lin et al., 2010), ochratoxin A (Sieber et al., 2009),
orning glory seed (dried mature seeds of Pharbitis nil (L.)
hoisy or Pharbitis purpurea (L.) Voigt (Ma  et al., 2010)), Cimi-
ifuga triterpenoid (He et al., 2012), cinnabar and realgar (Wei
t al., 2008, 2009) and Tripterygium wilfordii Hook (Xia et al.,
009).
.4. Applications to mushrooms
Amanita phalloides (Vaill. ex Fr.) link is a well-known exam-
le for hepatotoxicity (Vetter, 1998); it is less known but equally
elevant that -amanitin also exerts nephrotoxicity (Vogel et al.,
979). Cortinarius orellanus Fr., Cortinarius speciosissimus Kühner
 Romagnesi and other species of this genus contain a bipyridine,
rellanine, responsible for lethal tubular necrosis (Schumacher and
oiland, 1983; Tebbett and Caddy, 1984). As orellanine and the
ephrotoxic bipyridinium herbicides methylviologen (paraquat)
nd diquat have a similar chemical structure, a similar toxic-
ty mechanism has been controversially discussed for orellanine
Richard et al., 1995); it has been shown that oxygen radicals can be
enerated from the iron complex of orellanine (Richard et al., 1995;
antin-Esnault et al., 1998) and that antioxidant defense enzymes
re downregulated by orellanine (Nilsson et al., 2008). These few
xamples show that some musrooms bear a potential for nephro-
oxicity; knowledge about a global epidemiology of mushroom
oisonings has to be collected to prevent and treat new emerging
ushroom poisonings (Diaz, 2005).
Active hexose correlated compound (AHCC), a mushroom
xtract rich in -1,4 linked glucans, used in Japan as a dietary
upplement to boost immune function (Fujii et al., 2011) did not
how any evidence of kidney dysfunction in Sprague-Dawley rats.
he mushroom -glucan, a polymer of -(1,3/1,6)-glucan, has been
laimed for its health beneﬁts and no subchronic toxicity was found
n Sprague-Dawley rats (Chen et al., 2011a).
.5. General conclusions on nephrotoxicitySeveral methodological approaches have been developed to
ssess kidney toxicity of drugs. This reﬂects the need for comple-
entary methods to achieve a valuable nephrotoxicity screening. In
ddition, the safety evaluation needs to be focused on the materialarmacology 140 (2012) 492– 512 505
effectively taken by a subject. Indeed, it should be recognized that
there may  be signiﬁcant differences in pharmacokinetic behavior,
such as the rate or extent of absorption, and pharmacological/toxic
potency between a whole botanical and the equivalent amount of
an isolated active principle. In the large majority of cases, there
are no data available regarding metabolism and ADME study for a
given herbal medicine product. Despite several limitations, animal
models remain the gold standard to assess drugs nephrotoxicity. In
the future, animal models combined to ‘omics’ methods could be
useful to assess TCM nephrotoxicity.
5. Part D: opportunities, challenges and outlook of the
“omics” technologies in genotoxicity, teratogenicity, and
nephrotoxicity evaluation
5.1. Opportunities and challenges
Global analysis of genome-wide mRNA expression, protein and
metabolite patterns offers the potential: (i) to predict the toxic-
ity by establishing groups of chemicals causing the same type of
transcriptomics–proteomics–metabonomics proﬁle in a biological
system, i.e. toxic ﬁngerprinting; (ii) to discover the groups of genes
or proteins that are effective biomarkers for a given toxicity; (iii) to
elucidate the molecular mechanism of action of a xenobiotic; and
(iv) to predict the synergistic or inhibitory effects of compounds
in mixtures (Stierum et al., 2005; Xu et al., 2009; Villeneuve and
Garcia-Reyero, 2011).
Changes in transcriptomics, proteomics and/or metabonomics
proﬁles may  serve as early, sensitive indicators of a potential
toxicity and are thought to precede toxic outcomes (Aardema
and MacGregor, 2002). In particular, gene expression data (tran-
scriptomics) are thought to be more sensitive than traditional
toxicological endpoints (Searfoss et al., 2005). Toxicogenomics
can also help to bridge traditional in vitro and in vivo toxicity
assessment (Wilson et al., in press), and could be a very effective
tool in studying the safety of herbal medicines by expanding the
predictivity of potential toxicity in earlier stages of product devel-
opment (Amir-Aslani, 2008; Blomme  et al., 2009). Most literature
on “omics” technologies focuses on the pharmacological and toxi-
cological screening of new potential drugs (Knasmuller et al., 2008;
Ovesna et al., 2008; Chen and Cheng, 2009), but “omics” certainly
have their place in the toxicity assessment of plant-based medicinal
products, especially Chinese medicinal plants. Indeed, the integra-
tive approach of “omics” is in line with the holistic concept and
practices of TCM (Cho, 2007).
Despite their potential, there are a number of general challenges
to “omics” technologies applied to toxicology. These technolo-
gies are not standardized yet for all laboratories (Aardema and
MacGregor, 2002). So far, inter-laboratory evaluations of genomic
ﬁngerprints have demonstrated the need for caution in interpret-
ing the data; regulatory agencies are likely to face future challenges
with transcriptomics datasets coming from different laboratories,
models, strains and different durations of exposure. A wise use
of “data-rich omics” outputs will take time and validation, well-
trained experts and advanced capabilities for data analysis (Fielden
et al., 2008).
5.2. Outlook
In this post-genome era, a plethora of structural alerts and in
silico, in vitro and in vivo methods could be applied to predict the
genotoxicity, teratogenicity and nephrotoxicity of herbal medic-
inal products. The rapid progress in the power of bioinformatics
creates a great opportunity to employ “omics” technologies to cre-
ate a sound basis for better hazard identiﬁcation, for increased
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nderstanding of underlying mechanisms and for more relevant
enotoxicity assessment. However, these technologies are not stan-
ardized yet; this will be the main challenge for regulatory agencies
o overcome in establishing uniform and transparent methods to
nterpret and apply available “omics”.
Considering the aforementioned issues, it is critical that toxicol-
gists in industry, regulatory agencies and academic institutions
evelop rigorous “omics” methods to reach a consensus about the
eliability and interpretation of endpoints. It will also be impor-
ant to regulate the puzzle of conventional methods of genotoxicity
ssessments and their relation with new “omics” technologies. Fur-
hermore, investigations must be undertaken to discover novel
tructural alerts of toxicity from herbal medicinal products which
ill certainly facilitate an analytical assessment of traditional
edicinal plants toxicity at early stages of testing.
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